## Protocol Section
### Identification Module
**NCT ID:** NCT05110079

**Brief Title:** Revascularization of Total or Sub-total Occluded Peripheral Arteries With ByCross® Device. Post Market Clinical Followup

**Official Title:** Revascularization of Total or Sub-total Occluded Peripheral Arterial Vessels With ByCross

#### Organization Study ID Info
**ID:** QA 366-02
#### Organization
**Class:** INDUSTRY
**Full Name:** Taryag Medical Ltd.
### Status Module
#### Completion Date
**Date:** 2023-03-31

**Type:** ESTIMATED

#### Expanded Access Info
**Last Known Status:** RECRUITING
#### Last Update Post Date
**Date:** 2022-10-21

**Type:** ACTUAL

**Last Update Submit Date:** 2022-10-20

**Overall Status:** UNKNOWN

#### Primary Completion Date
**Date:** 2022-12-31

**Type:** ESTIMATED

#### Start Date
**Date:** 2021-06-02

**Type:** ACTUAL

**Status Verified Date:** 2021-10

#### Study First Post Date
**Date:** 2021-11-05
**Type:** ACTUAL
**Study First Submit Date:** 2021-10-26
**Study First Submit QC Date:** 2021-10-27
### Sponsor Collaborators Module

#### Lead Sponsor

**Class:** INDUSTRY

**Name:** Taryag Medical Ltd.

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** False

**Oversight Has DMC:** False

### Description Module

**Brief Summary:** Post market clinical follow up of Bycross® device.

**Detailed Description:** A prospective, multi-center, non-randomized, observational, post market clinical follow-up study of the ByCross® device to evaluate the safety, technical performance and effectiveness of the ByCross® device and effectiveness of the procedure using the device and adjunctive therapy.

The ByCross® is a single use, disposable, minimal invasive aspiration rotational atherectomy device. The ByCross® is aimed to enable effective revascularization and restore blood flow in peripheral occluded vessels. In cases that the artery is completely blocked such that opening is not possible with currently available solutions and the procedure cannot be completed, the device is capable of crossing the blocked lesion without guiding wire and enables the completion of the procedure in a safe and effective manner, thus potentially eliminating the need for open bypass surgery. The ByCross® can be used in several pathologies: calcified atheroma, old and fresh thrombus and in stent restenosis at peripheral arteries including iliac

### Conditions Module

**Conditions:**

- Peripheral Arterial Disease

### Design Module

#### Design Info

**Observational Model:** CASE_ONLY

**Time Perspective:** PROSPECTIVE

#### Enrollment Info

**Count:** 75

**Type:** ESTIMATED

**Study Type:** OBSERVATIONAL

### Arms Interventions Module

### Interventions

#### Intervention 1

**Description:** After assessment of the lesion by angiography the ByCross is advanced over a 0.035" guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage with guidewire is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the complete procedure is to achieved more than 70% opening.

**Name:** ByCross Atherectomy and Thrombectomy

**Type:** DEVICE

### Outcomes Module

#### Primary Outcomes

**Description:** Passage of the occlusion by the BYCROSS® device and post atherectomy residual stenosis ≤ 50% relative to reference diameter to allow for angioplasty and/or stenting if required, and complete procedural success of residual stenosis ≤ 30%

**Measure:** Acute procedure success

**Time Frame:** Up to 8 hours post-procedure

**Description:** Freedom, at any period between procedure and 90 days post procedure from device related Serious Adverse Events (SADEs) defined by the site as part of the normal reporting practice

**Measure:** Freedom from device related serious adverse events

**Time Frame:** 90 days follow up

#### Secondary Outcomes

**Description:** Rate of cases of vascular treatment in the same vessel treated during the study

**Measure:** Rate of Target vessel revascularization (TVR) at 12 months

**Time Frame:** 12 months

**Description:** Rate of cases of vascular re-intervention of the same lesion treated during the study

**Measure:** Rate of Target lesion revascularization (TLR) at 12 months

**Time Frame:** 12 months

**Description:** Improvement in Rutherford classification compared to pre-procedure

**Measure:** Rutherford classification improvement at 12 months

**Time Frame:** 12 months

**Description:** Rate of amputation of the limb treated during the study

**Measure:** Rate of amputations of at 12 months

**Time Frame:** 12 months

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* Subject has documented symptomatic chronic peripheral vascular disease at a vessel below the aorta bifurcation
* Candidate for percutaneous intervention
* Severely stenotic occlusion target vessel (stenosis ≥70%)
* Subject has been informed on the nature of the study and has provided informed consent
* Subject is capable of meeting study requirements including presences at follow-up visits

Exclusion Criteria:

* Patient anatomy excludes use of BYCROSS® device
* Vessels of the cardiopulmonary, coronary or cerebral circulations
* Undersized vessel diameters (\<3mm)
* Perforation of the vessel distally or proximally to the occlusion segment prior atherectomy
* Subintimal position of the guiding catheter or the guidewire
* Use in stents or stent grafts if the guidewire has become threaded at any point in the wire mesh of stent or stent graft or the lining of the stent graft
* Target is at vessel segment which includes tortuous course with radius of curvature \<= 40mm
* Access pathway includes tortuous course with radius of curvature \<= 25mm, in specific extremely sharp aortic bifurcation
* In aneurysmatically altered iliac vessel segments
* If the introducer sheath, the guide catheter, the guidewire or the BYCROSS® sustains any visible damage, especially kinking
* In the fracture areas of broken stents
* Known or suspected allergy to any of the components of the system or to a medicinal product to be administered in connection with the planned procedure
* Persistent vasospasm
* During use of a defibrillator on the patient

**Maximum Age:** 100 Years

**Minimum Age:** 18 Years

**Sampling Method:** NON_PROBABILITY_SAMPLE

**Sex:** ALL

**Standard Ages:**

- ADULT

- OLDER_ADULT

**Study Population:** Adult subjects (male and female) with limb ischemia requiring treatment and target vessel stenosis ≥ 70%

### Contacts Locations Module

#### Locations

**Location 1:**

**City:** Arnsberg

**Contacts:**

***Contact 1:***

- **Email:** s.mueller@klinikum-hochsauerland.de

- **Name:** Simone Muller

- **Phone:** +49 2932 952-244826

- **Role:** CONTACT

***Contact 2:***

- **Name:** Michael Lichtenberg, M.D.

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** Germany

**Facility:** Karolinen-Hospital, Klinik für Angiologie

**Status:** RECRUITING

**Zip:** 59755

**Location 2:**

**City:** Heidelberg

**Contacts:**

***Contact 1:***

- **Email:** Ilka.Buss@med.uni-heidelberg.de

- **Name:** Ilka Buss

- **Phone:** +49 6221 56-37920

- **Role:** CONTACT

***Contact 2:***

- **Name:** Christian Erbel, M.D.

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** Germany

**Facility:** Universitätsklinikum Heidelberg

**Status:** RECRUITING

**Zip:** 69120

**Location 3:**

**City:** Lingen

**Contacts:**

***Contact 1:***

- **Email:** Daniela.Viehweider@hospital-lingen.de

- **Name:** Daniela Viehweider

- **Phone:** 0591 910-6121

- **Role:** CONTACT

***Contact 2:***

- **Name:** Joerg Tessarek, M.D.

- **Role:** PRINCIPAL_INVESTIGATOR

**Country:** Germany

**Facility:** Bonifatius Hospital Lingen

**Status:** RECRUITING

**Zip:** 49808

#### Overall Officials

**Official 1:**

**Affiliation:** Bonifatius Hospital Lingen

**Name:** Joerg Tessarek, M.D.

**Role:** PRINCIPAL_INVESTIGATOR

### IPD Sharing Statement Module

**IPD Sharing:** NO

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000050197

- Term: Atherosclerosis

- ID: D000001161

- Term: Arteriosclerosis

- ID: D000001157

- Term: Arterial Occlusive Diseases

- ID: D000014652

- Term: Vascular Diseases

- ID: D000002318

- Term: Cardiovascular Diseases

### Condition Browse Module - Browse Branches

- Abbrev: BC14

- Name: Heart and Blood Diseases

- Abbrev: All

- Name: All Conditions

### Condition Browse Module - Browse Leaves

- ID: M29213

- Name: Peripheral Arterial Disease

- Relevance: HIGH

- As Found: Peripheral Arterial Disease

- ID: M18894

- Name: Peripheral Vascular Diseases

- Relevance: HIGH

- As Found: Peripheral Arterial Disease

- ID: M17400

- Name: Vascular Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M26188

- Name: Atherosclerosis

- Relevance: LOW

- As Found: Unknown

- ID: M4469

- Name: Arteriosclerosis

- Relevance: LOW

- As Found: Unknown

- ID: M4465

- Name: Arterial Occlusive Diseases

- Relevance: LOW

- As Found: Unknown

### Condition Browse Module - Meshes

- ID: D000058729

- Term: Peripheral Arterial Disease

- ID: D000016491

- Term: Peripheral Vascular Diseases

### Misc Info Module

- Version Holder: 2024-05-24
